Edition:
United Kingdom

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

12.71USD
15 Dec 2017
Change (% chg)

$0.09 (+0.71%)
Prev Close
$12.62
Open
$12.62
Day's High
$12.89
Day's Low
$12.01
Volume
2,868,057
Avg. Vol
263,273
52-wk High
$28.49
52-wk Low
$8.70

Select another date:

Thu, Nov 2 2017

BRIEF-Cara Therapeutics Inc reports Q3 loss per share $0.38

* Cara Therapeutics Inc reports third quarter 2017 financial results

BRIEF-Cara Therapeutics Q2 loss per share $0.29

* Cara Therapeutics reports second quarter 2017 financial results

BRIEF-Cara Therapeutics appoints Mani Mohindru CFO

* Cara Therapeutics appoints Mani Mohindru, Ph.D., chief financial officer

BRIEF-Cara Therapeutics says ‍phase 1 results showed all four tablet strengths of oral CR845 were generally well-tolerated​

* Cara Therapeutics announces summary data from phase 1 trial of oral cr845 in hemodialysis patients with chronic kidney disease

Cara's chronic pain drug data disappoints, shares plunge

Cara Therapeutics Inc reported disappointing data from a key study testing its chronic pain treatment in patients with osteoarthritis, sending the drug developer's shares down about 32 percent after the bell on Thursday.

UPDATE 1-Cara's chronic pain drug data disappoints, shares plunge

June 29 Cara Therapeutics Inc reported disappointing data from a key study testing its chronic pain treatment in patients with osteoarthritis, sending the drug developer's shares down about 32 percent after the bell on Thursday.

Cara reports mixed results from pain drug trial, shares plunge

June 29 Cara Therapeutics Inc on Thursday reported mixed results from a pivotal trial testing the drug developer's chronic pain treatment in patients with osteoarthritis of the knee or hip.

BRIEF-Cara Therapeutics announces top-line results from phase 2B trial

* Cara Therapeutics announces top-line results from phase 2B trial of oral CR845 in chronic pain patients with osteoarthritis of the hip or knee

BRIEF-Cara receives breakthrough therapy designation from FDA for I.V. CR845

* Cara receives breakthrough therapy designation from FDA for I.V. CR845 for the treatment of chronic kidney disease-associated pruritus in hemodialysis patients Source text for Eikon: Further company coverage:

BRIEF-Cara Therapeutics reports continuation of phase 3 trial of I.V. CR845 in postoperative pain

* Cara Therapeutics reports continuation of phase 3 trial of i.v. Cr845 in postoperative pain following interim assessment

Select another date: